Newswise — A group of scientists in California is trying to develop a cheaper, less invasive way to spot the early stages of retinal damage from diabetic retinopathy, the leading cause of blindness in American adults, before it leads to blindness. As described in the special Interactive Science Publishing (ISP) issue of Optics Express, the Optical Society's (OSA) open-access journal, the scientists are using beams of light to measure blood flow in the back of the eye. "The more severe the retinopathy, the lower the blood flow to the retina," says David Huang of the Center for Ophthalmic Optics and Lasers (www.COOLLab.net) at the Doheny Eye Institute of the University of Southern California in Los Angeles. This observation may lead to better ways to diagnose the condition early.
Diabetic retinopathy is caused by damage to blood vessels in the eye's retina. According to the U.S. Centers for Disease Control and Prevention, 5.5 million people over the age of 40 suffered from this condition in 2005, and this number is expected to triple by 2050 as the number of people with diabetes continues to increase. But there's hope; vision loss is preventable if retinal damage is detected early enough.
Affecting everyone who has type 1 diabetes and most people with type 2, diabetic retinopathy progresses in two stages. It begins when the small vessels that carry blood to and from the eye swell and leak, which can lead to slow vision loss as the health of the retina degenerates. In 20 percent of patients, the disease then progresses to advanced "proliferative" retinopathy. The oxygen-starved retina calls out to the circulatory system for help, which responds by forming new, abnormal blood vessels. These fragile vessels have thin walls that tend to scar and hemorrhage, causing sudden vision loss.
Huang and colleagues have adapted a spectroscopic technology called optical coherence tomography (OCT) -- normally used take cross-sectional pictures of the retina -- to directly detect the amount of blood flowing through retinal blood vessels. A diode on the OCT instrument beams infrared light into the blood vessel of interest. The frequency of light that bounces back is shifted slightly by the fast-moving blood, a Doppler effect similar to the pitch shift in the sound of a train as it rushes by.
Using this technique, the team estimated the total amount of blood flow in the retinal veins of two people with diabetes, to within 10 percent. They detected less blood flowing in the person who had advanced proliferative retinopathy. Further unpublished results in six more patients support this finding, but the next step, according to Huang, will be a larger clinical trial to verify this observation with statistical significance.
The most common method currently used by ophthalmologists to detect retinopathy is a fluorescein angiography, an injection of dye into retinal veins used to spot leaks. This moderately invasive technique can cause nausea and vomiting and, in rare cases, severe allergic reactions.
OCT may provide a more quantitative, less invasive way to diagnose the condition, says Huang. It also promises to be cheaper than other advanced detection techniques that require expensive equipment. "It just requires special scanning software that could easily be put on the OCT machines that most retinal specialists have," he says. He hopes that this combination of factors will give ophthalmologists an easy way to check for problems early and often.
Detecting leaky blood vessels early helps patients choose between different treatment options. "People with poor blood flow don't respond well to some of the laser treatments used for retinopathy, and they are at a higher risk for proliferative retinopathy," says Huang.
Huang's research takes advantage of ISP, an initiative undertaken by OSA in partnership with the National Library of Medicine, part of the National Institutes of Health, and with the support of the United States Air Force Office of Scientific Research. This initiative allows scientists to expand upon traditional research results by providing software for interactively viewing underlying source data and to objectively compare the performance of different technologies. This data may be related to medical images, such as those taken with X-rays, MRIs, CT scans and ultrasounds, or it may be created in research involving oil and gas exploration, climatology, pollution monitoring and many other fields. Specifically in this instance, researchers are able to look at the actual OCT scans from the study patients as they read the paper. The software was developed in conjunction with Kitware, Inc. For more information on ISP, visit http://www.opticsinfobase.org/isp.cfm.
Paper: "Retinal blood flow detection in diabetic patients by Doppler Fourier domain optical coherence tomography," Yimin Wang et al., Optics Express, Vol. 17, Issue 5, Mar. 2, 2009.
To set up interviews or for a copy of the paper, please contact Colleen Morrison, 202.416.1437, firstname.lastname@example.org.
About OSAUniting more than 70,000 professionals from 134 countries, the Optical Society (OSA) brings together the global optics community through its programs and initiatives. Since 1916 OSA has worked to advance the common interests of the field, providing educational resources to the scientists, engineers and business leaders who work in the field by promoting the science of light and the advanced technologies made possible by optics and photonics. OSA publications, events, technical groups and programs foster optics knowledge and scientific collaboration among all those with an interest in optics and photonics. For more information, visit www.osa.org.
About KitwareKitware, Inc. (http://www.kitware.com) is a leader in the creation and support of open-source software and state of art technology across five business areas: visualization, computer vision, medical imaging, data publishing and quality software process. By employing open source business and development models the company fosters extended, collaborative communities and provides flexible, low-cost technical solutions to medical device manufacturers, pharmaceutical companies, government researchers, the oil & gas industry, computer aided design & manufacturing, aerospace, engineering, and educational institutions worldwide.
Founded in 1998, Kitware has grown to include customers in over 43 countries and in 41 of the 50 US states. Kitware's team is widely recognized for their major contributions to a variety of open source software systems including the cross-platform build system CMake, the Visualization Toolkit (VTK), the Insight Segmentation and Registration Toolkit (ITK), and the Parallel Visualization System (ParaView).